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Abstract
Transforming growth factor b1 (TGF-b1) is a pleiotropic cytokine, which displays potent proﬁbrogenic eﬀects and is highly
expressed in ﬁbrotic livers. For this reason, development of TGF-b1 inhibitors might be of great importance to control liver
ﬁbrogenesis as well as other undesired side eﬀects due to this cytokine. Potential peptide inhibitors of TGF-b1 (derived from TGF-
b1 and from its type III receptor) were tested in vitro and in vivo using diﬀerent assays. Peptides P11 and P12, derived from TGF-b1,
and P54 and P144, derived from its type III receptor, prevented TGF-b1-dependent inhibition of MV1Lu proliferation in vitro and
markedly reduced binding of TGF-b1 to its receptors. P144 blocked TGF-b1-dependent stimulation of a reporter gene under the
control of human a2(I) collagen promoter. Intraperitoneal administration of P144 also showed potent antiﬁbrogenic activity in vivo
in the liver of rats receiving CCl4. These rats also showed a signiﬁcant decrease in the number of activated hepatic stellate cells as
compared with those treated with saline only. These results suggest that short synthetic peptides derived from TGF-b1 type III
receptor may be of value in reducing liver ﬁbrosis in chronic liver injury.
 2003 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Transforming growth factor b (TGF-b) is a family of
cytokines, which regulate the balance between cell mass
and extracellular matrix (ECM). Three members of the
TGF-b family (TGF-b1, TGF-b2 and TGF-b3) are
expressed in mammalian cells and tissues [1], and their
amino acid sequences are greater than 98% conserved
among species. These isoforms share many of their
biological activities and are able to stimulate their own
synthesis and that of their receptors [2]. TGF-b re-
ceptors have been categorized into ﬁve types: types I, II
and III are the most important because of their wide-
spread expression in many cell types. Types I and II form
a transmembrane complex that is able to transduce the
signal inside the cell, whereas type III captures TGF-b1
and presents it to the complex formed by types I and II re-
ceptors. In addition, soluble type III receptor acts as
a regulator of extracellular levels of active TGF-b1
(reviewed in Ref. [3]).
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TGF-b participates in a number of biological pro-
cesses including cell growth and diﬀerentiation, forma-
tion of ECM and modulation of the immune response
[1,4–7]. The biological eﬀects of TGF-b may be diﬀerent
in vitro and in vivo and are inﬂuenced by the functional
status of the target cell, by the interaction of the cells
with ECM components and by the presence or absence
of other cells in the extracellular milieu [8].
TGF-b regulates the equilibrium between the epithe-
lial tissue and ECM. TGF-b increases the deposition of
collagen and other ECM proteins by directly stimulating
expression of these genes and by inhibiting the synthesis
of collagenases [9]. TGF-b also enhances the production
of inhibitors of collagen degradation, such as plasmin-
ogen-activator inhibitor type 1 and tissue inhibitor of
metalloprotease [9]. In chronic viral hepatitis, the
expression of TGF-b in the liver closely correlates with
liver ﬁbrogenic activity [10,11]. Because of the potent
biological eﬀects mediated by TGF-b, it is clear that
pharmacological intervention to control TGF-b activity
may be of importance to inﬂuence a diversity of path-
ological processes including liver ﬁbrosis. In the present
study, we demonstrate that short peptide sequences
derived from TGF-b type III receptor eﬀectively
block several TGF-b1-mediated actions in vitro and
in vivo. They decrease activation of hepatic stellate
cells (HSCs), an ameliorate liver ﬁbrosis in rats treated
with CCl4 to produce cirrhosis.
2. Results
Synthetic peptide inhibitors of TGF-b1 binding to its
cell receptors were selected as follows: (i) overlapping
peptides encompassing the sequence of TGF-b1 and the
extracellular region of type III TGF-b1 receptor and (ii)
peptides from the TGF-b1 type III receptor predicted to
bind to TGF-b1 according to a computer program
developed in our laboratory (see Section 4). The activity
of these peptides was tested using MV1Lu cells in-
cubated with 200 pg/ml of TGF-b1, which inhibits
MV1Lu cell growth by 80–90% (data not shown), and
200 lg/ml of peptide. Peptide concentrations above
200 lg/ml were considered of no biological relevance.
Peptides with an activity of 40% or more (MV1Lu cell
assay) are shown in Table 1. All these peptides also
inhibited binding of biotinylated TGF-b1 to its recep-
tors in the ﬂow cytometry assay. Peptide P54 from rat
TGF-b1 type III receptor and P144 from the equivalent
region of human type III receptor were among the most
active.
Since P54 and P144, from rat and human TGF-b1
type III receptors, respectively, showed signiﬁcant TGF-
b1 inhibitory activities in the two systems used, and
might, therefore, possess potential therapeutic value, we
tested their ability to reduce TGF-b1-induced collagen
expression. Using a ﬁbroblast cell line, stably transfected
with a chimeric plasmid containing the TGF-b1-in-
ducible collagen a2(I) promoter linked to chloramphen-
icol acetyltransferase (CAT) gene [12,13]. It could be
argued that the use of HSCs might be more appropri-
ate to assess collagen promoter activity. However, we
decided to use the transfected ﬁbroblast cell line because
this line was available, and we wished to conﬁrm, by
a method other that the MV1Lu cell assay, that the most
active peptides were indeed able to block the activity of
TGF-b1. It was found that P54 and P144 inhibited CAT
expression in a dose-dependent manner (Fig. 1).
Liver ﬁbrosis is associated with increased levels of
TGF-b in hepatic tissue in a diversity of pathological
conditions both in humans [11,14] and in experimental
animal models [10,15]. To study whether TGF-b1
peptide inhibitors might be of value in reducing collagen
deposition in chronic liver injury, we tested the eﬀect of
P144 in a model of liver ﬁbrosis in the rat, induced by
exposure to CCl4 [16]. We tested the human type III
Table 1
Inhibition of human TGF-b1 by synthetic peptides from TGF-b1 and TGF-b1 type III receptors using two diﬀerent assays
% Inhibition of TGF-b1
Peptide Sequence of peptide Region of parent protein MV1Lu cell assayb Flow cytometry assayc
P11 HANFCLGPCPYIWSLA (318–332) Hum TGF-b1 40 96
P12 FCLGPCPYIWSLDTA (321–334) Hum TGF-b1 96 56
P106 SNPYSAFQVDIIVDIA (245–259) Rat TGF-b1 type III rec 40 94
P54 TSLDATMIWTMMA (730–742) Rat TGF-b1 type III rec 97 90
P144 TSLDASIWAMMQNA (729–742) Hum TGF-b1 type III rec 80 95
a The numbers in brackets correspond to the amino acid region of the corresponding protein. Accession numbers through PubMed databases for
Hum TGF-b1, Rat TGF-b1 type III receptor and Hum type III receptor are: XP008912, NP058952 and JC1350, respectively.
b Inhibition of TGF-b1 by peptides was quantitated by comparing the growth of MV1Lu cells cultured in the presence of 200 pg/ml of human
TGF-b1 with or without 200lg/ml of peptide (see Section 4).
c Inhibition of TGF-b1 by peptides was quantitated by measuring the binding of Avidin–FITC to biotinylated human TGF-b1 bound to TGF-b1
receptors from MV1Lu cells with or without 100lg/ml of peptide (see Section 4).
The alanine (in bold) was added at the C-terminal end of all peptides for synthesis convenience. Only those peptides with an activity 40% are
shown.
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receptor peptide P144 instead of the rat peptide P54, as
we are interested in using the TGF-b1 peptide inhibitors
in future therapy experiments in humans. Since P144
and P54 have only a few conservative diﬀerences in their
sequence, we reasoned that the human peptide P144
would be active in rats. If that were so, we would
validate the potential utility of P144 in humans. Rats
receiving CCl4 inhalations for 11 weeks (with a rest
during week 5) were treated with 70 lg of P144 i.p. on
alternate days during 6 weeks starting at week 6. A
control group of rats received CCl4 and saline instead of
peptide. Fibrosis was measured by two methods: (a)
estimation of the ratio between collagen and total pro-
tein of stained sections by spectrophotometry [17] and
(b) evaluation of collagen deposition by image analysis
in sections stainedwith Sirus red (see Section 4).As shown
in Fig. 2, the ratio of collagen to total protein in rats
receiving CCl4 was signiﬁcantly lower in rats treated
with P144 than in rats treated with saline only. The
antiﬁbrogenic eﬀect of P144 was conﬁrmed by image
analysis of the liver specimens. As shown in Fig. 3A, B,
collagen deposition was markedly reduced in CCl4-
treated rats that received P144, as compared with the
corresponding control group receiving saline only.
TGF-b has an antiproliferative action in MV1Lu
cells. However, TGF-b is the most important initiating
cytokine so far identiﬁed in cirrhosis because it pro-
motes collagen synthesis and stimulates proliferation of
HSCs [18,19]. In the carbon tetrachloride-induced ex-
perimental cirrhosis, HSCs undergo transformation
during the process of ﬁbrosis. During these changes,
the following events take place: (a) robust mitotic
activity in areas developing new parenchymal ﬁbrosis;
(b) shift from the resting-state lipocyte phenotype to
a transitional myoﬁbroblast phenotype; and (c) in-
creased capacity for synthesis and secretion of ECM.
Because activation of HSCs is associated with the
expression of a-smooth muscle actin (a-SMA) [20],
and this activation is the crucial event in ﬁbrosis [21],
immunostaining of a-SMA has been used to quantify
Fig. 1. Eﬀects of P54 (A) and P144 (B) on the inhibition of the TGF-b1-inducible reporter gene CAT driven by collagen a2(I) promoter. Bars
indicate the percentage of acetylation of radioactively labeled chloramphenicol by CAT in the presence or absence of diﬀerent concentrations of
inhibitor peptides. Experiments were carried out in triplicate. The percentage of inhibition of CAT expression (in brackets) was calculated by
measuring acetylation in the presence of diﬀerent concentrations of P54 or P144 according to the formula % inhibition¼ 100 100 (% acetylation
in the presence of TGF-b1 and inhibitor peptide% basal acetylation)/(% acetylation in the presence of TGF-b1% basal acetylation).
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the number of activated HSCs in experimental cirrhosis
in close relationship with ﬁbrosis.
In order to assess whether P144 was able to inhibit
HSC activation, we analyzed a-SMA by immunohisto-
chemistry in liver sections from rats, subjected to CCl4
inhalation, which received either P144 or saline. We
found that the number of a-SMA positive cells was
1059 330 per 30 high power ﬁelds in rats treated with
saline ðn ¼ 7Þ and 458 63 in those treated with P144
ðn ¼ 8Þ, resulting in a p, 0:05 between groups (Fig.
4A). The a-SMA immunoreactivity was mainly found in
bands of ﬁbrous tissue surrounding parenchymal nod-
ules. Fig. 4B shows representative sections of the liver
from the two groups of rats, in which a clear reduction
of a-SMA reactivity can be observed in those treated
with P144.
3. Discussion
TGF-b1 plays a critical role in the deposition of in-
creased amounts of collagens and other ECM proteins,
which accompany the development of liver cirrhosis
[11]. TGF-b1 is expressed in endothelial, hematopoi-
etic and connective-tissue cells [9]. In cirrhotic liver, HSCs
are the main source of this cytokine [22,23]. HSCs release
TGF-b1 after activation by lipid peroxidation pro-
ducts generated in various forms of hepatic injury includ-
ing viral, autoimmune and metabolic liver diseases and
alcohol abuse. TGF-b, in turn, causes HSC activation
and production of ECM proteins [24]. Liver ﬁbrosis
leads to portal hypertension by distorting liver architec-
ture. It also aﬀects liver function by altering hepatocyte
gene expression as a result of the interactionof the hepato-
cellular membrane with an abnormal ECM [25]. Thus,
eﬀorts to control liver ﬁbrosis by blocking TGF-b1
activity might be a useful therapeutic approach in cir-
rhotic patients or patients with liver conditions evolving
to cirrhosis.
In the present work, we have identiﬁed ﬁve peptides,
which are able to block the binding of TGF-b1 to its
cell receptor and antagonize TGF-b1 activity in vitro.
Two of these peptides (P11 and P12) are derived from
the TGF-b1 sequence and are encompassed by a longer
peptide previously described [26]. The other three
peptides (P54, P106 and P144) are from the sequence
of the extracellular region of type III TGF-b1 receptor.
Peptides P54 and P144 correspond to equivalent
regions of rat and human type III TGF-b1 receptors,
respectively; they were predicted as a potential binder
to TGF-b1 by a computer program developed in our
laboratory. Both P54 and P144 were able to block the
binding of TGF-b1 to its receptors, to counteract the
antiproliferative eﬀects of TGF-b1 on MV1Lu cells and
to inhibit TGF-b1-induced activation of collagen gene
expression in a ﬁbroblast cell line. Most importantly,
treatment with P144 at low doses caused a signiﬁcant
inhibition of HSC activation (Fig. 4A, C) and a marked
reduction in liver ﬁbrosis (Figs. 2 and 3) in a rat model
of chronic exposure to CCl4. All these data show that
P144 is able to inhibit TGF-b1 activity both in vitro
and in vivo, acting as a potent antiﬁbrogenic com-
pound.
In a previous study, George et al. [27] showed that
soluble type II TGF-b1 receptor (generated by fusion of
the extracellular region of type II receptor with the Fc
domain of human IgG1) was very eﬃcient at neutral-
izing TGF-b1 activity in vitro. This fusion protein at
doses of 5mg/kg reduced liver ﬁbrosis in rats (400 g
body weight) subjected to liver injury by laparotomy
and high ligation of the bile duct. In this study, we
demonstrated that a dose as low as 70 lg of the 15-mer
peptide P144, given to rats (300 g body weight) on
alternate days, decreased ﬁbrogenesis signiﬁcantly dur-
ing chronic exposure to CCl4. Thus, the two strategies to
inhibit TGF-b1 (based on type II or type III receptors,
respectively) appear to be eﬀective in reducing liver
ﬁbrosis. Further studies will be needed to analyze the
relative potency of these two forms of antiﬁbrogenic
intervention. Type III receptor is a non-signaling pro-
teoglycan cytokine receptor, which functions by binding
TGF-b1 and presenting it to the types I and II receptors
[9]. A great proportion of TGF-b1 is found in a latent
form attached to the ECM. Activation of TGF-b1
occurs by interaction of this latent form with certain
ECM glycoproteins, such as trombospondin 1 [28], or
by the eﬀect of some proteases, such as plasmin [29–31].
In summary, we have shown that short synthetic
peptides can be used to inhibit TGF-b1 activity in vitro
and in vivo. These compounds, or their modiﬁcations,
Fig. 2. Quantiﬁcation of collagen in liver sections from rats subjected
to CCl4 inhalation (weeks 1–11 with a period of rest during the whole
week 5). One group of eight rats (CCl4+P144) was treated with P144
(70lg i.p. from week 6 to week 11) and another group of eight rats
received saline (CCl4+saline). Co corresponds to eight healthy rats not
subjected to CCl4 inhalation. Values are represented using a box and
whisker plot, the height of the box being the interquartilic range and
the thick line, the median. The whiskers correspond to the highest
and lowest observations within 1.5 times the interquartilic range from
the edges of the box in both directions.
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might be of future interest to diminish ﬁbrosis in
processes, such as wound healing, chronic inﬂammatory
reactions or liver disease evolving to cirrhosis. Also,
because TGF-b1 is a pleiotropic cytokine and has potent
immunomodulatory functions [7], its blockage for
a prolonged period might have unwanted side eﬀects.
For this reason, extensive toxicity studies should be
carried out before using any TGF-b1 inhibitors in
humans. In the event that peptide p144 were found to be
toxic, in future experiments it could be envisaged to
administer a vector expressing P144 having tropism for
the liver (i.e. recombinant adenovirus). This might allow
to diminish the circulating levels of p144 without
decreasing the concentration at the site required.
4. Materials and methods
4.1. Selection of potential peptide inhibitors of TGF-b1
Potential peptide inhibitors of TGF-b1 were chosen us-
ing two diﬀerent strategies: (i) synthesizing overlapping
Fig. 3. Analysis of collagen in liver sections from rats submitted to CCl4 inhalation and treated with P144 (eight rats) or with saline (eight rats). (A)
Liver sections (10 ) stained with Sirus red from rats submitted to CCl4 inhalation. R1–R4 and R5–R8 correspond to eight representative sections
from rats treated with saline only or with peptide P144, respectively. (B) Analysis of the ratio between the area of ﬁbrosis and the total area of the
image from liver sections: (CCl4+saline) rats treated with saline only (n ¼ 8); (CCl4+P144) rats treated with P144 (n ¼ 8). Co corresponds to eight
normal rats not submitted to CCl4 inhalation nor to any other kind of treatment. Values are represented using a box and whisker plot, the height of
the box being the interquartilic range and the thick line the median. The whiskers correspond to the highest and lowest observations within 1.5 times
the interquartilic range from the edges of the box in both directions.
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peptides encompassing the whole sequence of TGF-b1,
and amino acids 44–418 from the extracellular region of
TGF-b1 type III receptor and (ii) predicting peptides
from TGF-b1 type III receptor (amino acids 1–853),
which might bind to TGF-b1. Predictions were made
using a program developed in our laboratory, which
assigns potential interactions between two peptides (one
from TGF-b1 and the other from a receptor protein of
TGF-b1) based on the hydrophilicity/hydrophobicity
and the net charge of the amino acid side chains from
both peptides. Basically, the program calculates a puta-
tive score of interaction between sequential blocks of 12
amino acids from both proteins. To calculate the score of
interaction between two blocks, the hydrophilicity of
amino acid at position 1 from the ﬁrst block is multiplied
by the hydrophilicity of amino acid at position 1 from the
second block, and so on till the amino acid at position 12.
The sum of these 12 products constitutes the score of
interaction between the two blocks. These calculations
were carried out using the amino acid hydrophilicity
scale of Hopp andWoods [32]. Since in the scale of Hopp
and Woods, the value of the hydrophilicity of hydro-
philic amino acids is positive, while the value of
hydrophobic amino acids is negative, higher scores are
obtained when two amino acids of the same type are
compared. However, since charged amino acid side
chains may attract or repel depending on their charge,
the products of the hydrophilicities between amino acid
side chains having the same sign of charge, Lys and Lys,
Arg and Arg, Lys and Arg, Asp and Asp, Glu and Glu
and Asp and Glu, were arbitrarily made negative to
penalize the interaction between these repelling side
chains. All other products were left unchanged.
4.2. Peptide synthesis
Peptides were synthesized by the solid phase method
[33] using the Fmoc alternative [34] as previously
described [35]. Peptides were at least 80% pure as per
HPLC.
4.3. Inhibition of MV1Lu cells by TGF-b1
and assay of peptide inhibitors of TGF-b1
TGF-b1 inhibits the growth of MV1Lu cells in vitro
[36]. Thus, inhibition of TGF-b1 by peptides re-
establishes cell growth. MV1Lu cells (ATCC) were
cultured to subconﬂuence in complete medium (RPMI
1640 containing L-glutamine and supplemented with 5%
fetal calf serum and antibiotics) at 37 C and 5% CO2 in
162 cm2 ﬂasks (Costar Corporation, CA, USA). Cells
(5 103/well) were cultured in a 96 ﬂat well plate (Costar
Corporation) at 37 C, 5% CO2 overnight to allow cell
adhesion. Diﬀerent peptide concentrations (or 200 lg/ml
for initial screening assays) plus TGF-b1 (200 pg/ml)
were added to the wells. After 24 h incubation, 1 lCi of
Fig. 4. Activated HSCs in the liver of rats subjected to CCl4 inhalation
and treated with saline or P144. (A) The number of a-SMA positive
cells (presented as meanSD) per 30 random high power ﬁelds was
determined. A signiﬁcant decrease in the number of activated HSCs
was observed in the group of rats treated with CCl4+P144 as com-
pared with those that received saline; (B) representative liver section
immunostained with antia-SMA from rats treated with CCl4+saline
( 200) and (C) representative liver section from rats treated with
CCl4+P144 showing a lower number of positive cells stained for a-
SMA ( 200).
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(methyl-3H)-thymidine (Amersham Life Science, Buck-
inghamshire, UK) was added per well and incubated for
12 h. Cells were harvested (Titertek Cell Harvester Inc.,
Sterling, USA) and radioactivity measured on a b-
scintillation counter (Beta plate system, LKB, Uppsala,
Sweden). As positive and negative controls, we used
MV1Lu cells grown in the absence or presence of TGF-
b1, respectively. Inhibition of TGF-b1 was calculated
using the formula
% inhibition
¼ 100 ðcpmpeptide tested  cpmnegative controlÞ=
ðcpmpositive control cpmnegative controlÞ
Negative control represents cells in the presence of
TGF-b1, but without peptide, whereas positive control
corresponds to cells without TGF-b1 or peptide.
4.4. Study of the inhibition of binding of TGF-b1
to its receptors by ﬂow cytometry
Peptide inhibition of TGF-b1 binding to its receptors
was studied by ﬂow cytometry using the Fluorokine
TGF-b-biotin kit (R&D Systems) according to manu-
facturer’s instructions. Brieﬂy, MV1Lu cells were in-
cubated with peptide (100 lg/ml), in the presence of
biotinylated TGF-b1 for 1 h. Avidin–FITC was then
added and the ﬂuorescence measured. As positive and
negative controls, we measured cell ﬂuorescence after
adding, biotinylated TGF-b1 and Avidin–FITC, or
Avidin–FITC only, respectively. Inhibition was calcu-
lated using the formula
% inhibition
¼ 100 ððmf peptidemf negative controlÞ
100=ðmf positive controlmf negative controlÞÞ
mf peptide is the mean ﬂuorescence of cells having bound
biotinylated TGF-b1 in the presence of peptide that was
tested; mf negative control: mean ﬂuorescence of cells in
the absence of biotinylated TGF-b1; mf positive control:
mean ﬂuorescence of cells having bound biotinylated
TGF-b1 in the absence of peptide tested.
4.5. Eﬀect of the TGF-b-inhibiting peptide
on the stimulation of collagen a2(I)
promoter function by TGF-b1
Primary human fetal skin ﬁbroblast cells (CF37)
stably transfected with a chimeric plasmid containing
the TGF-b1-inducible collagen a2(I) promoter linked to
CAT gene were used as previously described [12,13].
Brieﬂy, ﬁbroblasts were grown at 37 C and 5% CO2 for
3 h in Dulbecco’s modiﬁed Eagle’s medium containing
4.5 g/l of glucose supplemented with 10% fetal bovine
serum (FBS) (Hyclone, Logan, UT, USA) and 150 lg/
ml of hygromicin B. After washing with PBS, cells were
suspended in fresh medium containing inhibitor peptide
tested, BSA 0.2%, FBS 0.4%, TGF-b1 (8 ng/ml)
(Boehringer) and incubated in six-well plates for 67 h.
Cells were trypsinized and centrifuged at 14,000 rpm for
1min. The pellet was re-suspended in 100 ll of ice-cold
0.25M Tris, pH 7.5 and lysed by three freeze–thaw
cycles. Cytoplasmic extracts isolated at 4 C and
14,000 rpm for 5min were incubated at 37 C with
acetyl CoA and 2 ll (200 lCi/ml) of 14C-labeled chlor-
amphenicol for 1 h. Acetylation was stopped adding 1ml
of ethyl acetate and centrifuging at 14,000 rpm at 4 C
for 1min. The ethyl acetate phase was vacuum-dried
overnight and extracted with fresh ethyl acetate (30 ll).
Mono-acetylated and non-acetylated chloramphenicol
from these extracts were separated by thin-layer
chromatography in chloroform–methanol 19 : 1 (v/v)
using sheets of plastic-backed, silica gel 1B (J.T. Baker)
for 1 h. Percentage of acetylation was calculated using
the 860 PhosphorImager Storm (Molecular Dynamics)
apparatus and the Imagequant program.
%acetylation
¼ ðcounts inmono acetylated speciesÞ
100=ðcounts inmono acetylated species
þ counts in non acetylated chloramphenicolÞ:
Percentage inhibition of TGF-b1 by peptides was
calculated according to
% inhibition
¼ 100 100 ð%acetylation in the presence of
TGF-b1 and peptide%basal acetylationÞ=
ð%acetylation in the presence of TGF-b1
%basal acetylationÞ:
4.6. Immunohistochemistry and quantiﬁcation
of activated HSC
Immunohistochemical staining for a-SMA [20] was
performed on formalin-ﬁxed and paraﬃn-embedded
tissues. Sections were deparaﬃnized with xylene and
treated with 0.01M citrate buﬀer (pH 6) in a microwave
(800W) at maximum power for 5min. Specimens were
then incubated at room temperature with a monoclonal
antibody to a-SMA (Dako A/S, Copenhagen, Den-
mark). Antibody detection was carried out using the
Envision kit (Dako) following the manufacturer’s
instructions. Slides were counterstained weakly with
Mayer’s hematoxylin, dehydrated and mounted. Nega-
tive controls were performed using PBS instead of the
primary antibody. Estimation of the number of antia-
SMA immunoreactive was done by a blinded observer
counting positive cells in 30 random high power ﬁelds
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( 400). Counting of a-SMA positive cells was carried
out in the entire ﬁeld without making any distinction if
the positive cells were around or inside the nodules.
4.7. Induction of liver ﬁbrosis by CCl4
Hepatic ﬁbrosis was induced in Wistar rats by
inhalation of CCl4 [37] twice a week as previously
described [16]. Rats received CCl4 until end of week 11
(with a rest during week 5) and injected 70 lg of the
TGF-b1-blocking peptide i.p. on alternate days from the
beginning of week 6 until the end of week 11. A control
group of rats received saline instead of the peptide. All
animals were treated according to the guidelines from
our institution (CIFA, Pamplona, Spain).
4.8. Analysis of collagen in liver sections
Deposition of collagen in the liver was evaluated as
follows. (i) Liver sections were stained with Fast green
and Direct red and the stain eluted with methanol and
sodium hydroxide. Collagen and total protein were
estimated by spectrophotometry at 540 and 630 nm,
respectively [17]. (ii) Image analysis of Sirus red-stained
liver sections using polarized light microscopy and
a green ﬁlter was performed.
4.9. Statistical analysis
Statistical analysis was carried out using the com-
puter program SPSS for Windows. Comparison between
groups was carried out using the Kruskal–Wallis test
followed by Mann–Whitney’s U test. The statistical
analysis of inhibition of CAT with synthetic peptides,
was done using the Shapiro–Wilk test ð p ¼ 0:773Þ
followed by the Dunnett test.
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